The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

Anteris Technologies Global Corp.’s AVR share price has dipped by 5.20%, which has investors questioning if this is right ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Mark Wilterding; Mark Wilterding Senior Vice President, Investor Relations and Treasurer; Edwards Lifesciences Corp. Bernard Zovighian; President, Chief Executive Of ...

Ahmedabad: Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited specializing in medical ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

Piper Sandler upgraded Edwards Lifesciences (EW) to Overweight from Neutral with a price target of $80, up from $73. The firm sees a “better ...

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...